New hemophilia drug tested as replacement therapy

NCT ID NCT06703606

Recruiting now Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

Summary

This study is testing whether people with severe hemophilia A can safely switch from their current preventive medication (emicizumab) to a new one (marstacimab). Researchers want to see how the body handles the new drug and check for side effects. The study involves about 15 participants aged 12-75 who have been on emicizumab for at least 6 months.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE HEMOPHILIA A are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ege University Faculty of Medicine Dean's Office
RECRUITING

Bornova, İzmir, 35100, Turkey (Türkiye)
K J Somaiya Hospital & Research Centre
RECRUITING

Mumbai, Maharashtra, 400022, India
Nirmal Hospital Pvt Ltd.
RECRUITING

Surat, Gujarat, 395002, India
Orthopaedic Institute for Children/Orthopaedic Hemophilia Treatment Center
RECRUITING

Los Angeles, California, 90007, United States

Conditions

Explore the condition pages connected to this study.

SEVERE HEMOPHILIA A